Fundraising Fox
BioCytics
Huntersville, US · Delaware corporation
Find your way into BioCytics
Sign up to see every warm intro you have to BioCytics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the BioCytics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
BioCytics conducts translational cancer research, including a project with UNC Charlotte and Carolina BioOncology Institute to study the "dark genome" of cancer cells to identify sequences involved in tumor growth, immune response, and treatment response. Its work spans cell therapy, neoantigens, tumor infiltrating lymphocytes, and clinical research informatics.
Founders & leadership
JP
John PowderlyFounder & CEODr. Powderly founded Carolina BioOncology Institute in 2005, an independent phase I cancer center in North Carolina, and has published extensively on immunotherapy and cancer research in peer-reviewed journals. He currently serves as President & CEO of BioCytics and holds adjunct clinical faculty positions at Duke and UNC.
RW
Renaud WarinChief Scientific OfficerHe brings expertise in immunology, molecular biology, and cell characterization, with experience in regulated environments including FDA and cGMP settings, and a background in immune cell isolation and modification for cancer therapeutics.
MP
Matthew PietrasNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$1.4M disclosed across 3 rounds · 2023–2026
▶$25KraisedMar 2026 · 1 investors · BiotechnologyRule 506(b)
▶$25KraisedMar 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John PowderlyExecutive Officer, Director
- Jim PowderlyExecutive Officer
- Offering amount
- $7M
- Amount sold
- $25K
- Minimum investment
- $25K
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25KraisedDec 2023 · 1 investors · Other Health CareRule 506(b)
▶$25KraisedDec 2023 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Don L. JacksonExecutive Officer
- Jim PowderlyExecutive Officer
- John PowderlyExecutive Officer, Director
- Stacy PowderlyExecutive Officer
- Offering amount
- $4M
- Amount sold
- $25K
- Minimum investment
- $25K
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.4MraisedMar 2023 · 18 investors · Other Health CareRule 506(b)
▶$1.4MraisedMar 2023 · 18 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- John PowderlyExecutive Officer, Director
- Matthew PietrasExecutive Officer
- Jim PowderlyExecutive Officer
- Offering amount
- $8M
- Amount sold
- $1.4M
- Minimum investment
- $25K
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does BioCytics do?
- BioCytics conducts translational cancer research, including a project with UNC Charlotte and Carolina BioOncology Institute to study the "dark genome" of cancer cells to identify sequences involved in tumor growth, immune response, and treatment response. Its work spans cell therapy, neoantigens, tumor infiltrating lymphocytes, and clinical research informatics.
- Who founded BioCytics?
- BioCytics was founded by John Powderly.
- How much funding has BioCytics raised?
- BioCytics has disclosed $1.4M raised across 3 rounds.
- Where is BioCytics headquartered?
- BioCytics is headquartered in Huntersville, US.